COMPARATIVE EFFICACY OF FIRST-LINE DOCETAXEL plus CAPECITABINE (XT) VERSUS DOCETAXEL plus EPIRUBICIN (ET): POOLED ANALYSIS OF TWO RANDOMISED TRIALS

被引：0
|
作者：
Luporsi, E. [1 ]
Bachelot, T. [2 ]
Bajard, A. [3 ]
Chinal, J. Provencal [4 ]
Coeffic, D. [5 ]
Platini, C. [6 ]
Marcel, D. Dramais [7 ]
Oprea, C. [8 ]
Ferri-Dessems, R. [9 ]
Perol, D. [2 ]
机构：
[1] Ctr Alexis Vautrin, F-69373 Vandoeuvre Les Nancy, France
[2] Ctr Leon Berard, Lyon, France
[3] Hop Univ Strasbourg, Strasbourg, France
[4] CH Reg Annecy, Annecy, France
[5] Inst Privet Cancel, Grenoble, France
[6] Hop Bon Secours, Metz, France
[7] CH Valence, Valence, France
[8] Sanofi Aventis, Paris, France
[9] Gmo Oncohematol, Roche, Neuilly Seine, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [1] Randomized trial of first-line docetaxel plus capecitabine (XT) versus docetaxel plus epirubicin (ET) for metastatic breast cancer (MBC): Efficacy results of ERASME-4/CAPEDOC-EPIDOC
    Bachelot, T.
    Luporsi, E.
    Bajard, A.
    Provencal, J.
    Coefic, D.
    Platini, C.
    Dramais, D.
    Oprea, C.
    Ferri-Dessens, R.
    Perol, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Syrigos, K.
    Kakolyris, S.
    Ziras, N.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 48 - 54
  • [3] A Pooled Analysis of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer
    Seidman, Andrew D.
    Chan, Stephen
    Wang, Jin
    Zhu, Chao
    Xu, Cong
    Xu, Binghe
    ONCOLOGIST, 2014, 19 (05): : 443 - 452
  • [4] Superiority of Docetaxel plus Capecitabine Compared to Docetaxel plus Epirubicin as First-Line Therapy for Metastatic Breast Cancer - Final Results of the ERASME-4 Study.
    Bachelot, T.
    Bajard, A.
    Ray-Coquard, I
    Coeffic, D.
    Dramais, D.
    Ferri-Dessens, R.-M.
    Guastalla, J.-P.
    Perol, D.
    CANCER RESEARCH, 2009, 69 (24) : 625S - 625S
  • [5] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    T Gamucci
    A M D'Ottavio
    E Magnolfi
    M Barduagni
    A Vaccaro
    I Sperduti
    L Moscetti
    F Belli
    L Meliffi
    British Journal of Cancer, 2007, 97 : 1040 - 1045
  • [6] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    Gamucci, T.
    D'Ottavio, A. M.
    Magnolfi, E.
    Barduagni, M.
    Vaccaro, A.
    Sperduti, I.
    Moscetti, L.
    Belli, F.
    Meliffi, L.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1040 - 1045
  • [7] DOCETAXEL PLUS EPIRUBICIN VERSUS DOCETAXEL PLUS CAPECITABINE AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED BREAST CANCER. FINAL RESULTS OF A MULTICENTER PHASE III TRIAL
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Kakolyris, S.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Geirgoulias, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [8] Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung
    Lu, S.
    Chen, Z.
    Hu, C.
    Xin-Ling, R.
    Chen, Y.
    Song, Y.
    Qiong, Z.
    Fan, Y.
    Gang, W.
    Zhi-Yong, M.
    Fang, J.
    Qi-Tao, Y.
    Liu, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1807 - S1808
  • [9] Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer
    Amarantidis, K.
    Xenidis, N.
    Chelis, L.
    Chamalidou, E.
    Dimopoulos, P.
    Michailidis, P.
    Tentes, A.
    Deftereos, S.
    Karanikas, M.
    Karayiannakis, A.
    Kakolyris, S.
    ONCOLOGY, 2011, 80 (5-6) : 359 - 365
  • [10] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
12345